IN2012DN02711A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02711A IN2012DN02711A IN2711DEN2012A IN2012DN02711A IN 2012DN02711 A IN2012DN02711 A IN 2012DN02711A IN 2711DEN2012 A IN2711DEN2012 A IN 2711DEN2012A IN 2012DN02711 A IN2012DN02711 A IN 2012DN02711A
- Authority
- IN
- India
- Prior art keywords
- glucose
- animal
- amg
- gastrointestinal
- sglt
- Prior art date
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 4
- 230000002496 gastric effect Effects 0.000 abstract 4
- 239000008103 glucose Substances 0.000 abstract 4
- HOVAGTYPODGVJG-ZFYZTMLRSA-N methyl alpha-D-glucopyranoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-ZFYZTMLRSA-N 0.000 abstract 3
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000029142 excretion Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 abstract 1
- 108091052347 Glucose transporter family Proteins 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229940121377 sodium-glucose co-transporter inhibitor Drugs 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24257009P | 2009-09-15 | 2009-09-15 | |
| PCT/US2010/048752 WO2011034846A1 (en) | 2009-09-15 | 2010-09-14 | Use of alpha-methylglucoside (amg) as an indicator for glucose absorption and excretion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02711A true IN2012DN02711A (enExample) | 2015-09-11 |
Family
ID=42983318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2711DEN2012 IN2012DN02711A (enExample) | 2009-09-15 | 2010-09-14 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8147801B2 (enExample) |
| EP (1) | EP2478357A1 (enExample) |
| JP (1) | JP5722901B2 (enExample) |
| CN (1) | CN102597770B (enExample) |
| AU (1) | AU2010295722B2 (enExample) |
| IN (1) | IN2012DN02711A (enExample) |
| WO (1) | WO2011034846A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111655298B (zh) * | 2017-11-21 | 2023-02-03 | 索尔维克斯有限公司 | 包含氘代3-o-甲基葡萄糖用于肿瘤疾病磁共振的诊断制剂以及使用所述制剂的诊断方法 |
| JP7570663B2 (ja) | 2020-07-22 | 2024-10-22 | 国立大学法人群馬大学 | 糖尿病、肥満および／または脂肪肝に対する新規診断マーカーおよび新規治療用組成物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2345250T3 (es) * | 2002-08-08 | 2010-09-20 | Kissei Pharmaceutical Co., Ltd. | Derivado de pirazol en la composicion medicinal que contiene el mismo, el uso medicinal del mismo, y un intermedio para la produccion del mismo. |
| ZA200501094B (en) * | 2002-08-08 | 2006-10-25 | Kissei Pharmaceutical | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| AU2003275713A1 (en) | 2002-10-29 | 2004-05-25 | Takeda Pharmaceutical Company Limited | Use of sglt homolog |
| JP2005015460A (ja) * | 2002-10-29 | 2005-01-20 | Takeda Chem Ind Ltd | Ｓｇｌｔホモログ用途 |
| EP1601795A4 (en) * | 2003-03-07 | 2008-03-26 | Threshold Pharmaceuticals Inc | METHOD FOR DETERMINING THE SENSITIVITY OF A TUMOR AGAINST TREATMENT WITH AN ANTI-TUMBER AGENT |
| CN103819465A (zh) * | 2003-08-01 | 2014-05-28 | 田边三菱制药株式会社 | 新颖化合物 |
| WO2005011592A2 (en) * | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted indazole-o-glucosides |
| JP2005139093A (ja) * | 2003-11-05 | 2005-06-02 | Nichirei Corp | グルコース吸収阻害剤およびその製造方法 |
| AR053329A1 (es) * | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt) |
| TWI418556B (zh) * | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | 吲哚衍生物 |
| TW200904454A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
| JP2009155212A (ja) * | 2007-12-25 | 2009-07-16 | Taisho Pharmaceutical Co Ltd | Ｃ−フェニル１−チオグルシト−ル化合物を有効成分とする糖尿病治療剤 |
-
2010
- 2010-09-14 IN IN2711DEN2012 patent/IN2012DN02711A/en unknown
- 2010-09-14 US US12/881,695 patent/US8147801B2/en not_active Expired - Fee Related
- 2010-09-14 JP JP2012529847A patent/JP5722901B2/ja not_active Expired - Fee Related
- 2010-09-14 AU AU2010295722A patent/AU2010295722B2/en not_active Ceased
- 2010-09-14 CN CN201080051671.0A patent/CN102597770B/zh not_active Expired - Fee Related
- 2010-09-14 EP EP10755292A patent/EP2478357A1/en not_active Withdrawn
- 2010-09-14 WO PCT/US2010/048752 patent/WO2011034846A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20110065200A1 (en) | 2011-03-17 |
| EP2478357A1 (en) | 2012-07-25 |
| JP5722901B2 (ja) | 2015-05-27 |
| JP2013504769A (ja) | 2013-02-07 |
| AU2010295722A1 (en) | 2012-04-12 |
| WO2011034846A1 (en) | 2011-03-24 |
| CN102597770B (zh) | 2016-08-10 |
| US8147801B2 (en) | 2012-04-03 |
| CN102597770A (zh) | 2012-07-18 |
| AU2010295722B2 (en) | 2015-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013010952A2 (pt) | sistemas de rmn e métodos para a detecção rápida de analisados | |
| GB2459228A (en) | Exosome-associated microrna as a diagnostic marker | |
| EP4335932A3 (en) | Methods of monitoring conditions by sequence analysis | |
| WO2010091049A3 (en) | Diagnosis and treatment of cancer | |
| WO2011015602A3 (en) | Lung cancer biomarkers | |
| WO2009085234A3 (en) | Use of micro-rna as a biomarker of immunomodulatory drug activity | |
| WO2009025852A3 (en) | Methods of using mirna for detection of in vivo cell death | |
| MX2008014679A (es) | Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry. | |
| AR081696A1 (es) | Anticuerpo para el diagnostico y/o pronostico de cancer | |
| MX2010014228A (es) | Metodos y productos de diagnostico del p/gf-1 acompañante. | |
| ATE512681T1 (de) | Dialysesystem mit nichtinvasiver temperaturmessung | |
| MX2013000916A (es) | Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales. | |
| WO2008057437A3 (en) | Ex vivo flow cytometry method and device | |
| WO2008021290A3 (en) | Organ-specific proteins and methods of their use | |
| ZA201100035B (en) | Diagnostic sample collection system | |
| EP2209495A4 (en) | TAZ / WWTR1 FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
| FR2919060B1 (fr) | Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal. | |
| EP2585826A4 (en) | METHODS AND COMPOSITIONS FOR DIAGNOSING AND PROGNOSING RENAL INJURY AND RENAL FAILURE | |
| GB0711327D0 (en) | Diagnostic method | |
| WO2010028373A3 (en) | Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients | |
| WO2012006056A3 (en) | Ccr6 as a biomarker of alzheimer's disease | |
| BR112014009223A2 (pt) | método para o diagnóstico da doença de niemann-pick | |
| FR2904450B1 (fr) | Systeme de simulation de capteur. | |
| AP2012006182A0 (en) | Detecting PAX2 for the diagnosis of breast cancer. | |
| WO2010017524A3 (en) | System, method and computer accessible medium for providing real-time diffusional kurtosis imaging |